In a note issued yesterday (30 November) on Schroder UK Public Private trust (SUPP), Investec said it remained concerned about the medium-term outlook and the “immature portfolio and legacy issues” were likely to be a drag on returns as it downgraded the trust to a sell.
The former Woodford Patient Capital trust has benefited from the legacy invest in Oxford Nanopore, which contributed 94% of the Q3 NAV increase of 15.9%, according to Investec. The biotech firm set an offer price of 425 pence per share, which would have given the firm a total market capitalisation of approximately £3.4bn. However, the stock opened considerably higher at 545 pence per share before rising as high as 622 pence per share, up 47% on its initial offer price. However, away from the success of the IPO the trust is struggling with the portfolio it inherited from Neil Woodford....
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
